

# Lung Cancer: Small Cell Lung Cancer Pathways

---

Patient Name: \_\_\_\_\_

Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_

Treatment Start Date: \_\_\_\_\_

Pathology: \_\_\_\_\_

Stage: \_\_\_\_\_

Line of Therapy: \_\_\_\_\_

ICD-10 Code: \_\_\_\_\_

## Adjuvant Therapy

- Limited Stage
  - With or without concurrent radiation therapy
    - Carboplatin and etoposide
    - Cisplatin and etoposide

## Neoadjuvant Therapy, Primary Therapy, First Line Therapy

- Limited Stage
  - With or without concurrent radiation therapy
    - Carboplatin and etoposide
    - Cisplatin and etoposide
- Extensive Stage
  - Atezolizumab (Tecentriq), carboplatin, and etoposide
  - Carboplatin and etoposide

## Second Line of Therapy

- Extensive/Recurrent Stage
    - Tarlatamab-dlle (Imdelltra)
- 

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered “on pathway.” However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.